High density lipoproteins enhance the Na+/H+ antiport in human platelets

Thrombosis and Haemostasis

Volumn 75, Issue 4, 1996, Pages 635-641

  Nofer, Jerzy Roch ^a   Tepel, Martin ^b   Kehrel, Beate ^c   Walter, Michael ^a,b   Seedorf, Udo ^b   Assmann, Gerd ^a,b   Zidek, Walter ^b  

^a Institut fur Klinische Chemie   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Innere Medizin A   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIPORTER; BISINDOLYLMALEIMIDE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HIGH DENSITY LIPOPROTEIN; INDOMETACIN; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE C INHIBITOR; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SUBERIMIDIC ACID DIMETHYL ESTER; THROMBIN; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE;

ARTICLE; CALCIUM CELL LEVEL; CELL PH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GLANZMANN DISEASE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SODIUM CELL LEVEL; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 0029971432     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650335     Document Type: Article

References (48)

1. Gordon T, Rifkind BM. High density lipoproteins - the clinical implication of recent studies. N Engl J Med 1989; 321: 1311-5.
2. Assmann G, von Eckardstein A, Funke H. High density lipoproteins, Reverse transport of cholesterol, and coronary artery disease: Insights from mutations. Circulation 1993; 87 (suppl III): III28-III34.
3. Suria I, Akkermann J-WN. The influence of lipoproteins on blood platelets. Am Heart J 1992; 125: 272-5.
4. Bierenbaum ML, Fleischmann AI, Stier A, Watson P, Somol H, Naso AM, Binder M. Increased platelet aggregation and decreased high-density lipoprotein cholesterol in women on oral contraceptives. Am J Obstet Gynecol 1979; 134: 638-41.
5. Aviram M, Brook G. Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis 1983; 13: 344-50.
6. Aviram M, Brook G. Platelet interaction with high and low density lipoproteins. Atherosclerosis 1983; 46: 259-68.
7. Higashihara M, Kinoshita M, Shoji K, Teramoto T, Kurokawa K. Inhibition of platelet function by high density lipoprotein from a patient with apolipoprotein E deficiency. Biochem Biophys Res Commun 1991; 181: 1331-6.
8. 2) formation by washed platelets under the influence of low and high density lipoproteins. Prostaglandins Leukotriens Med 1986; 23: 303.
9. 2). Prostaglandins Leukotriens and Essential Fatty Acids 1989; 35: 37-40.
10. IIIIn-labeled HDL to platelets from normolipemic volunteers and patients with heterozygous familial hypercholesterolemia. Arteriosclerosis Thromb 1992; 12: 849-61.
11. Curtiss LK, Plow EF. Interaction of plasma lipoprotein with human platelets. Blood 1984; 64. 365-74.
12. Koller E, Koller F, Doelschel W. Specific binding sites on human blood platelets for plasma lipoproteins. Hoppe-Seyler's Z Physiol Chem 1982; 363: 395-405.
13. Koller E, Koller F, Binder VR. Purification and identification of the lipoprotein binding proteins from human blood platelet membranes. J Biol Chem 1989; 264: 12412-8.
14. 3 modulate platelet aggregation by activation of protein kinase C. Circulation (Suppl.) 1993; 8: 457.
15. 3 activated phospholipase C in human platelets. Arteriosclerosis Thromb 1994; 14: 1321-6.
16. 3 stimulated platelets. Thromb Res 1990; 59: 913-20.
17. Nazih H, Devred D, Martin-Nizard F, Clavey V, Fruchart JC, Delbart C. Pertussis toxin sensitive G-protein coupling of HDL receptor to phospholipase C in human platelets. Thromb Res 1992; 67: 559-67.
18. 3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. Biochem Biophys Res Comm 1995; 207: 148-54.
19. Siffert W. Regulation of platelet function by sodium hydrogen exchange. Cardiovasc Res 1995; 29: 160-6.
20. 2+-dependent binding of a synthetic peptide Arg-Gly-Asp (RGD) to a single site on the purified platelet glycoprotein IIb/IIIa-complex. J Biol Chem 1989; 264: 13102-8.
21. Havel RJ, Eder H, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1995; 3: 1345-53.
22. Lowry OH, Rosebrough NJ, Farn AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
23. Chaco GK, Mahlberg FH, Johnson WJ. Cross-linking of apoproteins in high density lipoproteins by dimethylsuberimidate inhibits specific lipoprotein binding to membranes. J Lipid Res 1988; 28: 319-27.
24. Thomas JA, Buchsbaum RN, Zimniak A, Racker E. Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes generated in situ. Biochemistry 1979; 81: 2210-8.
25. + exchanger activity in normotensive and hypertensive subjects: effect of enalapril therapy upon antiport activity. J Hypertens 1992; 10: 839-47.
26. 2+ influx by a tyrosine kinase dependent pathway. J Biol Chem 1994; 269: 26239-42.
27. 1 increase activates sodium influx in human platelets. Biochem Biophys Acta 1994; 1220: 248-52.
28. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
29. 2+ influx pathway. J Biol Chem 1991; 266: 13153-60.
30. + in human platelets. Biochem Biophys Acta 1993; 1176: 215-21.
31. Kilsdonk EPC, van Gent T, Dorsman ANRD, van Tol A. Binding of modified high density lipoproteins to endothelial cells: relation with cellular cholesterol efflux? Atherosclerosis 1992; 97: 131-42.
32. Andrews HE, Aitken JW, Hassal DG, Skinner VO, Bruckdorfer KR. Intracellular mechanisms in the activation of human platelets by low-density lipoproteins. Biochem J 1987; 242: 559-64.
33. + exchange in lymphocyte by phorbol esters: Change in cytoplasmic pH dependence of the antiport. Proc Natl Acad Sci USA 1985, 82: 1429-33.
34. +-exchanger isoform 1 (HNE 1) is a novel member of calmodulin-binding proteins. Identification and characterization of calmodulin-binding sites. J Biol Chem 1994; 269: 13703-9.
35. 2+-regulation defective. J Biol Chem 1994; 269: 13703-9.
36. 2+ and protein kinase C. J Biol Chem 1990; 265: 21068-74.
37. + exchange. J Biol Chem 1988; 263: 4223-7.
38. +-exchanger isoforms. Am J Physiol 1995; 268: C283-C296.
39. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74: 1181-90.
40. Mendez AJ, Oram JF, Bierman EL. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem 1991; 266: 10104-11.
41. Theret N, Delbart C, Aguie G, Fruchart JC, Vassaux G, Ailhaud G. Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation. Biochem Biophys Res Comm 1990; 173: 1361-8.
42. 3 stimulates multiple signalling pathways in human fibroblasts. Arterioscler Thromb and Vasc Biol 1995; 15: 1975-86.
43. + exchange is not necessary for protein kinase C-mediated effects in platelets. FEBS Lett 1989; 252: 147-52.
44. + exchange is inhibitory to secretion induced by some agonists. FEBS Lett 1989; 250: 195-200.
45. + exchange, is necessary for receptor-mediated arachidonate release in platelets. Biochem J 1990; 265: 155-60.
46. 1 rises evoked by thrombin and PAF in human platelets. Europ J Pharm 1986; 128: 99-107.
47. 2+] and pH in human platelets. Cytoplasmic alkalinization is not prerequisite for calcium mobilization. Biochem Biophys Acta 1988; 938: 497-500.
48. 2+ fluxes in human platelets. J Biol Chem 1990; 11522-6.